Injectable Immunotherapy Shrinks Precancerous Oral Lesions In Clinical Trial

Injecting nivolumab (Opdivo) straight into precancerous oral lesions led to simplification successful lesion size and allowed immoderate patients to debar surgery, according to investigation from a shape I objective proceedings presented astatine nan American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

Approximately 5% of nan wide organization person precancerous lesions successful their rima that tin transportation a 1% to 36% consequence of progression to oral cancer, depending connected nan grade of dysplasia (i.e., really abnormal nan cells of nan lesion are) and different factors, explained presenter Moran Amit, MD, PhD, a surgeon and adjunct professor astatine The University of Texas MD Anderson Cancer Center. Since location are nary reliable biomarkers to foretell nan consequence of progression, galore patients typically acquisition surgical resection of their lesions, but this process is associated pinch precocious morbidity, he said.

"The rima is nan main conduit to truthful galore different functions, including speaking, eating, drinking, and breathing. Think astir nan past clip you had a sore spot successful your mouth, really debilitating that was. Now ideate a diligent who has to acquisition room astatine galore locations successful their mouth, complete and complete again arsenic nan lesions recur," said Amit, noting that astir 60% of patients coming pinch aggregate lesions and that nan consequence of recurrence aft room tin beryllium arsenic precocious arsenic 40%.

Each clip a diligent has to acquisition surgery, they are losing measurement of their oral cavity, astir commonly connected nan tongue. Once you suffer a definite magnitude of your tongue, you cannot articulate anymore, you cannot swallow effectively. Because of precancerous lesions, patients tin suffer their expertise to speak and eat. The nonsubjective of our study was to find a measurement to spare patients from this oftentimes debilitating surgery."

Moran Amit, MD, PhD, surgeon and adjunct professor, The University of Texas MD Anderson Cancer Center

Prior investigation has indicated that curen pinch nan immune checkpoint inhibitor nivolumab could trim nan size and progression consequence of precancerous oral lesions, but this treatment, which is delivered systemically done intravenous infusion, comes pinch terrible toxicities, said Amit.

"While effective, systemic nivolumab tin lead to toxicities that would not beryllium acceptable for patients who do not moreover person crab yet," he noted.

Amit and colleagues reasoned that injecting a little dose (2% to 4% of nan intravenous dose) of nivolumab straight into nan oral lesion could efficaciously dainty nan lesion without inducing nan systemic toxicities associated pinch intravenous nivolumab.

To trial this hypothesis, they conducted a shape I objective proceedings to measure nan information and efficacy of intralesional nivolumab.

The proceedings enrolled 29 patients pinch astatine slightest 1 histologically confirmed, untreated premalignant oral lesion that had a precocious consequence of progression to oral crab owed to its size, location, morphology, aliases grade of dysplasia, aliases nan patient's property aliases aesculapian history. More than half of nan lesions were located connected nan tongue. Fifteen patients had lesions pinch high-grade (moderate aliases severe) dysplasia; nan remaining 14 patients had low-grade (mild) dysplasia.

Patients received either 10 mg aliases 20 mg of nivolumab injected straight into 1 of their oral lesions each 3 weeks for a full of 4 cycles. The proceedings protocol allowed curen of only 1 lesion per diligent successful bid to measure whether intralesional nivolumab's effects would beryllium systemic aliases restricted to nan tract of injection. In instances wherever patients had much than 1 lesion, nan largest lesion was chosen for treatment.

After a median follow-up of 14.5 months aft nan first injection, 25 of 29 patients (85%) had knowledgeable a objective response, defined arsenic a alteration successful lesion size. Lesion area decreased by an mean of 60%, and 19 patients knowledgeable reductions greater than 50%. Clinical responses were observed for lesions that were high-grade and those that were low-grade astatine baseline. Twelve patients (41%) knowledgeable histologic downgrading of their treated lesion, and six patients had complete pathologic response, meaning their treated lesion had nary signs of dysplasia astatine nan clip of follow-up. Of nan six patients pinch complete pathologic response, 4 had mean dysplasia earlier treatment, and 2 had mild dysplasia.

Twelve months aft treatment, 82.13% of treated lesions continued to beryllium crab free. For nan six patients whose treated lesions progressed to cancer, nan progressions were detected early, and nan lesions were surgically removed. None of nan patients whose lesions didn't advancement required aliases opted for surgical resection of their treated lesions during nan follow-up time.

Serum levels of nivolumab were consistently 10-fold little than typically observed pinch systemic administration. No dose-limiting toxicities occurred pinch intralesional treatment. The astir communal adverse events were fatigue, diarrhea, and rash. Mild injection-site reactions occurred successful 40% of injections but resolved wrong 48 hours without intervention. Most adverse events were people 1 aliases 2, but location was 1 lawsuit each of people 3 diarrhea, people 3 hyperglycemia, and people 4 acidosis.

All but 4 enrolled patients completed each curen cycles and monitoring. Patients' symptoms, specified arsenic those related to swallowing, rima and pharynx soreness, voice, communication, taste, and nutrition, either improved aliases remained unchangeable during curen and follow-up, according to patient-reported outcomes. Patients reported greater enjoyment of life and accrued beingness activity aft curen arsenic compared pinch baseline.

The researchers besides examined insubstantial samples from 23 patients to find really intralesional nivolumab impacted nan immune microenvironment of treated and untreated lesions. They observed immune activation exclusively successful nan treated lesions, arsenic indicated by greater infiltration of CD4+ T cells, CD8+ T cells, and activated dendritic cells, arsenic good arsenic immune-cell interactions suggestive of adaptive immune responses. Untreated lesions from nan aforesaid patients did not grounds immune changes, which, according to Amit, suggests that intralesional transportation efficaciously constricted nivolumab's usability to target sites.

"Our findings show that intralesional transportation of nivolumab is safe, good tolerated, and results successful efficacy rates unparalleled by different nonsurgical methods, which allowed america to spare room for nan mostly of patients-spare removal of pieces of their mouth, whether it's nan tongue, nan cheek, nan level of their mouth, aliases their palate," said Amit. "Even if a diligent ends up undergoing room later, nan mean 60% simplification successful lesion size from intralesional nivolumab intends we tin substantially minimize nan magnitude of room they'll request down nan road, which would hopefully construe to a overmuch little effect connected their value of life."

Amit noted that nan findings whitethorn person implications beyond oral lesions. "Many crab types are preceded by precursor lesions, specified arsenic those arising connected nan skin, cervix, aliases colon. Our results raise nan anticipation that section immunotherapy management could beryllium an effective interception strategy for those precancerous lesions arsenic well."

Limitations of nan study see nan single-arm design, short follow-up time, and nan truth that nan study was not statistically powered to measure efficacy.

The study was supported by nan Cancer Prevention and Research Institute of Texas.